AN2 Therapeutics
Market cap $161M 37.9M shares (10-Q, Nov 5, 2026) × $4.23 close Nov 17, 2026
Most recent annual filing: 2026-03-17
- AN2-502998 Chagas Ph2 startLate 2026 (guided): Chagas Phase 2 start with DNDiAN2-502998 Chagas Ph2 start, Late 2026 (guided): Chagas Phase 2 start with DNDi, routine
- AN2 Therapeutics corporate updateNov 2026AN2 Therapeutics corporate update, Nov 2026, routine
- Epetraborole PV interim2027Epetraborole PV interim, 2027, major
- Divesiran competitor Ph3 start1H 2027Divesiran competitor Ph3 start, 1H 2027, routine
- Silence Therapeutics / Merck KGaA1Q 2027Silence Therapeutics / Merck KGaA, 1Q 2027, routine
- PN-8047 Protagonist Ph1 start1Q 2027PN-8047 Protagonist Ph1 start, 1Q 2027, routine
- AN2-502998 Chagas Ph2 topline2H 2027AN2-502998 Chagas Ph2 topline, 2H 2027, major
- AN2-504661 HPP corporate update2H 2027AN2-504661 HPP corporate update, 2H 2027, routine
- NIAID melioidosis funding corporate updateJul 2027NIAID melioidosis funding corporate update, Jul 2027, routine
- Epetraborole REBOUND toplineLate 2027 (guided): REBOUND toplineEpetraborole REBOUND topline, Late 2027 (guided): REBOUND topline, major
- AN2 Therapeutics options repricing corporateSep 19, 2027AN2 Therapeutics options repricing corporate, Sep 19, 2027, routine
- Epetraborole PV Ph3 readout~2028Epetraborole PV Ph3 readout, ~2028, notable
- Epetraborole composition patent litigation rulingJun 2028Epetraborole composition patent litigation ruling, Jun 2028, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (6 active programs)
AN2-502998
AN2-503321
AN2-504661
- Hypophosphatasia
Technology platforms
Boron Chemistry Platform · GSK
Boron-based small molecule discovery platform enabling high ligand efficiency against difficult or undruggable targets; current focus areas include infectious diseases (Chagas disease, NTM/M. abscessus, melioidosis, tuberculosis) and oncology (ENPP1, PI3Kα solid-tumor targets); has produced first-in-class molecules against CPSF3 and LeuRS targets
Targets: LeuRS, PI3Kα, ENPP1, CPSF3
Boron Chemistry Platform
Proprietary boron chemistry research and development platform enabling discovery of small-molecule inhibitors with unique binding modes against targets considered undruggable or difficult to access; focus areas include infectious diseases, oncology (PI3Kα), and rare metabolic diseases (ENPP1 for hypophosphatasia). Platform has produced first-in-class molecules against CPSF3 and LeuRS targets.
Targets: ENPP1, PI3Kα, CPSF3, LeuRS
Boron Chemistry
Boron-based small molecule discovery platform enabling novel binding modes against difficult or undruggable targets; current disease focus includes infectious diseases (NTM, Chagas), hematologic diseases (polycythemia vera), oncology (solid tumors), and bone disorders. Known target classes include CPSF3, LeuRS, ENPP1, and PI3Kα.
Targets: PI3Kα, ENPP1, LeuRS, CPSF3
boron chemistry platform · Gates Foundation
Boron chemistry platform for discovery and development of novel small molecule therapeutics; disease focus spans hematologic diseases, infectious diseases and oncology, including tuberculosis, malaria, melioidosis, and bone disorders.
Discontinued (1)
- epetraborole — Mycobacterium avium Complex Lung Disease · Phase 3 portion of EBO-301 study failed to meet primary endpoint; development discontinued
Capital (as filed)
- Cash
- $20.2M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $44.2M Sep 30, 2026
- Long-term investments
- $15.8M Sep 30, 2026
- Operating cash flow
- −$6.1M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $80.2M cash, runway into 2029 per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (2)
- 2026-11-10 UPDATE: AN2 Therapeutics (ANTX) - The IND Lands, the Clock Starts 🔒 Paid
- 2026-10-27 AN2 Therapeutics (ANTX) - Scientific Deep Dive for Epetraborole and AN2-502998 and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (2 calls)
Every verdict Biotech Distilled has published on AN2 Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-10-27 Watch AN2 Therapeutics (ANTX) - Scientific Deep Dive for Epetraborole and AN2-502998 and Pipeline Products The PV thesis rests on an adverse event in non-PV patients with a controlled effect smaller than phlebotomy-dependent patients need and a platelet signal pointing the wrong way; wait for PV Part 1 data showing hematocrit control without a platelet problem before taking a position.
- 2026-11-10 Watch UPDATE: AN2 Therapeutics (ANTX) - The IND Lands, the Clock Starts IND cleared on schedule and cash covers all 2027 readouts, but no PV patient has been dosed and the scientific case is unchanged; maintain Watch until PV Part 1 data demonstrate hematocrit control without a platelet problem.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (3 quotes from 2 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“The 84-patient multicenter, randomized, double-blind, placebo-controlled, prospective clinical study is being led by Dr. Kevin Winthrop, Professor of Public Health and Infectious Diseases at the Oregon Health and Science University, in conjunction with other investigators across an estimated 10-15 sites in the U.S. We anticipate reporting topline results in late 2027, subject to enrollment progress.”
matched to Epetraborole (M. abscessus, REBOUND) · topline data
-
-
-
“We expect to initiate a Phase 2 proof-of-concept study in adults with chronic Chagas disease in late 2026.”
matched to AN2-502998 (Chagas) · topline data -
“The 84-patient multicenter, randomized, double-blind, placebo-controlled, prospective clinical study is being led by Dr. Kevin Winthrop, Professor of Public Health and Infectious Diseases at the Oregon Health and Science University, in conjunction with other investigators across an estimated 10-15 sites in the U.S. We anticipate reporting topline results in late 2027, subject to enrollment progress.”
matched to Epetraborole (M. abscessus, REBOUND) · topline data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (22)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Nov 2, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 9, 2026ReleaseAN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific Highlights→ BD updateSummary on the 8-K
- Nov 9, 20268-KCurrent report: results of operations · EX-99.1→ BD updateThe FDA IND for EBO-PV-201 has cleared — the single most important execution milestone the thesis was waiting for — and the Q3 10-Q reveals the ATM printed ~1.4M shares in Q3 alone, with $80.2M cash still intact and runway "into 2029."
- Nov 9, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 4, 2026ReleaseAN2 Therapeutics to Present at Jefferies Global Healthcare Conference in London
- Nov 4, 2026ReleaseAN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)
- Nov 2, 2026ReleaseAN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera
- Aug 11, 20268-KCurrent report: results of operations · EX-99.1
- Aug 11, 202610-QQuarterly report
- Jun 9, 20268-KCurrent report: shareholder vote
- Jun 4, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- May 11, 20268-KCurrent report: results of operations · EX-99.1
- May 11, 202610-QQuarterly report
- Apr 22, 2026DEFA14AProxy soliciting material
- Apr 22, 2026DEF 14AProxy statement
- Apr 20, 2026424B5Prospectus supplement (offering)
- Apr 20, 2026424B3Prospectus (resale / update)
- Apr 9, 2026S-3Shelf registration
- Apr 9, 20268-KCurrent report: other events
- Mar 20, 20268-KCurrent report: officer / director change
- Mar 17, 20268-KCurrent report: results of operations · EX-99.1
- Mar 17, 202610-KAnnual report
- Mar 10, 20268-KCurrent report: material agreement, unregistered sale of equity, Reg FD disclosure · EX-99.1
14 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 13, 2026SCHEDULE 13G/A13G amendment
- Nov 13, 2026SCHEDULE 13G/A13G amendment
- Sep 14, 2026S-8Employee plan registration
- May 15, 2026SCHEDULE 13G/A13G amendment
- Apr 22, 2026ARSAnnual report to shareholders
- Apr 20, 2026EFFECTRegistration effective
- Apr 16, 2026CORRESPCORRESP
- Apr 15, 2026UPLOADUPLOAD
- Mar 25, 2026DForm D (exempt offering)
- Mar 17, 2026S-8Employee plan registration
- Mar 16, 2026SCHEDULE 13GPassive >5% holder (13G)
- Mar 13, 2026SCHEDULE 13GPassive >5% holder (13G)
- Mar 13, 2026SCHEDULE 13GPassive >5% holder (13G)